Oric Pharmaceuticals Inc (ORIC) - News Archive

: The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) continues to challenge clinicians due to inherent and acquired therapeutic resistance. In recent developments, ORIC Pharmaceuticals h...

Enozertinib: A New Era in Targeted Cancer TherapyIn the rapidly advancing field of oncology, the quest for effective treatments that specifically target resistance mechanisms in cancer cells has led to groundbreaking in...

CSIMarket.com Insight: ORIC Pharmaceuticals’ Strategic Position and Market Dynamics In an era where innovation in oncology is paramount, ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical-stage company that primarily...

Company Continues to Build Talent Pool Amid Promising Oncology DevelopmentsSOUTH SAN FRANCISCO, Calif. and SAN DIEGO May 02, 2025 ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical-stage oncology company dedicated to...

ORIC Pharmaceuticals Set to Illuminate Investor Conferences Amidst Promising Therapeutic Developments In a strategic move indicative of its commitment to transparency and stakeholder engagement, ORIC Pharmaceuticals, In...

In recent developments within the pharmaceutical landscape, ORIC Pharmaceuticals Inc. has outlined its strategic registrational clinical development plans aimed at enhancing its lead programs while simultaneously extend...

ORIC Pharmaceuticals Announces Latest Inducement Grants Amidst Growth MomentumSouth San Francisco, Calif. and San Diego Feb. 7, 2025 - ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical-stage oncology firm at the for...

In the rapidly evolving field of oncology, where the relentless pursuit of innovative treatments often dictates market dynamics, companies must not only discover new therapeutic avenues but also cultivate a skilled work...

ORIC Pharmaceuticals Bolsters Workforce with Significant Inducement Grants, Reflecting Ambitious Growth PlansSOUTH SAN FRANCISCO, Calif. and SAN DIEGO ORIC Pharmaceuticals Inc. (Nasdaq: ORIC), a clinical stage oncology...

In its latest move to strengthen its workforce and commitment to oncology breakthroughs, ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) has announced the granting of inducement stock options and restricted stock units to thr...

South San Francisco, Calif. and San Diego, Aug. 02, 2024 - ORIC Pharmaceuticals, a clinical-stage oncology company dedicated to developing innovative treatments that address mechanisms of therapeutic resistance, has rec...

Potential Game-Changer in Prostate Cancer Treatment: ORIC Pharmaceuticals Innovative CollaborationsIn a significant stride towards advancing the treatment landscape for metastatic castration-resistant prostate cancer (m...

In the competitive realm of oncology research and drug development, ORIC Pharmaceuticals Inc. has recently made significant strides in bolstering its workforce through the issuance of inducement grants. These grants, aw...

IntroductionORIC Pharmaceuticals, Inc., a pioneering clinical-stage oncology company, has recently announced the issuance of inducement grants as part of its steadfast commitment to oncology breakthroughs. The grants, w...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4), Bolstering Workforce and Promoting Commitment to Oncology BreakthroughsSOUTH SAN FRANCISCO and SAN DIEGO, May 03, 2024 - ORIC Pharmace...

ORIC Pharmaceuticals Makes Strides in Advancing Targeted Therapies for Mutated NSCLC, Metastatic Prostate Cancer, and Multiple MyelomaORIC Pharmaceuticals, a renowned clinical-stage biopharmaceutical company specializin...

brings you the latest findings from ORIC Pharmaceuticals, as presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting. The company showcased promising preclinical data on two of their program...

ORIC Pharmaceuticals, a leading clinical-stage oncology company, made an exciting announcement today regarding the granting of inducement options and restricted stock units to two new non-executive employees. The grant...

ORIC Pharmaceuticals Secures $125 Million in Private Placement Financing and Reinforces Workforce with Inducement Grants, Reinforcing Commitment to Oncology BreakthroughsIn a bid to strengthen its position in the field...

Metastatic prostate cancer, a devastating disease that affects thousands of men worldwide, requires innovative approaches to improve patient outcomes. ORIC Pharmaceuticals, a pioneering biopharmaceutical company, has re...